Relation Between Neutrophil-To-Lymphocyte Ratio and Mortality in Patients with Hypertrophic Cardiomyopathy

References

• Gerull B , KlaassenS, BrodehlA. The genetic landscape of cardiomyopathies. In: Genetic Causes of Cardiac Disease.ErdmannJ, MorettiA. ( Eds). Springer International Publishing, Cham, Switzerland, 45–91 (2019).
   Google Scholar
• Maron BJ . Hypertrophic cardiomyopathy. Lancet350(9071), 127–133 (1997).
   PubMed Web of Science ®Google Scholar
• Maron BJ , OlivottoI, SpiritoPet al. Epidemiology of hypertrophic cardiomyopathy-related death. Circulation102(8), 858–864 (2000).
   PubMed Web of Science ®Google Scholar
• Lamke GT , AllenRD, EdwardsWD, TazelaarHD, DanielsonGK. Surgical pathology of subaortic septal myectomy associated with hypertrophic cardiomyopathy: a study of 204 cases (1996–2000). Cardiovasc. Pathol. (3), 149–158 (2003).
   PubMed Web of Science ®Google Scholar
• Kuusisto J , KärjäV, SipolaPet al. Low-grade inflammation and the phenotypic expression of myocardial fibrosis in hypertrophic cardiomyopathy. Heart98(13), 1007–1013 (2012).
   PubMed Web of Science ®Google Scholar
• Zen K , IrieH, DoueTet al. Analysis of circulating apoptosis mediators and proinflammatory cytokines in patients with idiopathic hypertrophic cardiomyopathy. Int. Heart J.46(2), 231–244 (2005).
   PubMed Web of Science ®Google Scholar
• Högye M , MándiY, CsanádyM, SeppR, BuzásK. Comparison of circulating levels of interleukin-6 and tumor necrosis factor-alpha in hypertrophic cardiomyopathy and in idiopathic dilated cardiomyopathy. Am. J. Cardiol.94(2), 249–251 (2004).
   PubMed Web of Science ®Google Scholar
• Iwasaki J , NakamuraK, MatsubaraHet al. Relationship between circulating levels of monocyte chemoattractant protein-1 and systolic dysfunction in patients with hypertrophic cardiomyopathy. Cardiovasc. Pathol.18(6), 317–322 (2009).
   PubMed Web of Science ®Google Scholar
• Zhu L , ZouY, WangYet al. Prognostic significance of plasma high-sensitivity C-reactive protein in patients with hypertrophic cardiomyopathy. J. Am. Heart Assoc.6(2), 1–8 (2017).
   Web of Science ®Google Scholar
• Jhuang YH , KaoTW, PengTCet al. Neutrophil-to-lymphocyte ratio as predictor for incident hypertension: a 9-year cohort study in Taiwan. Hypertens. Res.42(8), 1209–1214 (2019).
   PubMed Web of Science ®Google Scholar
• Sun X , LuoL, ZhaoX, YeP, DuR. The neutrophil-to-lymphocyte ratio on admission is a good predictor for all-cause mortality in hypertensive patients over 80 years of age. BMC Cardiovasc. Disord.17(1), 1–9 (2017).
   PubMedGoogle Scholar
• Silberman S , FinkD. Neutrophil-to-lymphocyte ratio and risk of atrial fibrillation. Am. J. Cardiol.123(11), 1889 (2019).
   PubMed Web of Science ®Google Scholar
• Cosansu K , VatanMB, GunduzH, AkdemirR. Use of neutrophil-lymphocyte ratio for risk stratification and relationship with time in therapeutic range in patients with nonvalvular atrial fibrillation: a pilot study. Am. J. Cardiol. Clin. Cardiol.41(3), 339–342 (2018).
   Google Scholar
• Arbel Y , FinkelsteinA, HalkinAet al. Neutrophil/lymphocyte ratio is related to the severity of coronary artery disease and clinical outcome in patients undergoing angiography. Atherosclerosis225(2), 456–460 (2012).
   PubMed Web of Science ®Google Scholar
• Paliogiannis P , FoisAG, SotgiaSet al. Neutrophil-to-lymphocyte ratio and clinical outcomes in copd: recent evidence and future perspectives. Eur. Respir. Rev.27(147), 1–10 (2018).
   Web of Science ®Google Scholar
• Annibali O , HohausS, MarchesiFet al. The neutrophil/lymphocyte ratio ≥3.5 is a prognostic marker in diffuse large B-cell lymphoma: a retrospective analysis from the database of the Italian regional network ‘Rete Ematologica del Lazio per i Linfomi’ (RELLI). Leuk. Lymphoma60(14), 3386–3394 (2019).
   PubMed Web of Science ®Google Scholar
• Lin AJ , GangM, RaoYJet al. Association of posttreatment lymphopenia and elevated neutrophil-to-lymphocyte ratio with poor clinical outcomes in patients with human papillomavirus-negative oropharyngeal cancers. JAMA Otolaryngol. Head Neck Surg.145(5), 413–421 (2019).
   PubMed Web of Science ®Google Scholar
• Zamorano JL , AnastasakisA, BorgerMAet al. 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the task force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology (ESC). Eur. Heart J.35(39), 2733–2779 (2014).
   PubMed Web of Science ®Google Scholar
• Wang Z , LiaoH, HeS, ChenX. Performance and validation of R-CHA2DS2VASc score for thromboembolism in patients with hypertrophic cardiomyopathy. Hell. J. Cardiol.1–5 (2019).
   PubMed Web of Science ®Google Scholar
• He S , WangZ, CheemTH, LiaoH, ChenX, HeY. External validation of the model of thromboembolic risk in hypertrophic cardiomyopathy patients. Can. J. Cardiol.35(12), 1800–1806 (2019).
   PubMed Web of Science ®Google Scholar
• Lang RM , BadanoLP, VictorMAet al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J. Am. Soc. Echocardiogr.28(1), 1–39.e14 (2015).
   PubMed Web of Science ®Google Scholar
• Zahorec R . Ratio of neutrophil-to-lymphocyte counts – rapid and simple parameter of systemic inflammation and stress in critically ill. Bratisl. Lek. Listy102(1), 5–14 (2001).
   PubMedGoogle Scholar
• Khor KH , CampbellFE, OwenH, ShielsIA, MillsPC. Myocardial collagen deposition and inflammatory cell infiltration in cats with pre-clinical hypertrophic cardiomyopathy. Vet. J.203(2), 161–168 (2015).
   PubMed Web of Science ®Google Scholar
• Liu S , ChirkovYY, HorowitzJD. Neutrophil-initiated myocardial inflammation and its modulation by B-type natriuretic peptide: a potential therapeutic target. Int. J. Mol. Sci.20(1), 129 (2019).
   Web of Science ®Google Scholar
• Raman B , ArigaR, SparteraMet al. Progression of myocardial fibrosis in hypertrophic cardiomyopathy: mechanisms and clinical implications. Eur. Heart J. Cardiovasc. Imaging20(2), 157–167 (2019).
   PubMed Web of Science ®Google Scholar
• Abo T , KawamuraT. Immunomodulation by the autonomic nervous system: therapeutic approach for cancer, collagen diseases, and inflammatory bowel diseases. Ther. Apher.6(5), 348–357 (2002).
   PubMedGoogle Scholar
• Katarzynska-Szymanska A , OchotnyR, Oko-SarnowskaZet al. Shortening baroreflex delay in hypertrophic cardiomyopathy patients - an unknown effect of β-blockers. Br. J. Clin. Pharmacol.75(6), 1516–1524 (2013).
   PubMed Web of Science ®Google Scholar
• Ozyilmaz S , AkgulO, UyarelHet al. The importance of the neutrophil-to-lymphocyte ratio in patients with hypertrophic cardiomyopathy. Rev. Port. Cardiol.36(4), 239–246 (2017).
   PubMedGoogle Scholar
• Fest J , RuiterTR, GrootKoerkamp Bet al. The neutrophil-to-lymphocyte ratio is associated with mortality in the general population: The Rotterdam Study. Eur. J. Epidemiol.34(5), 463–470 (2019).
   PubMed Web of Science ®Google Scholar
• Sun X , LuoL, ZhaoX, YeP, DuR. The neutrophil-to-lymphocyte ratio on admission is a good predictor for all-cause mortality in hypertensive patients over 80 years of age. BMC Cardiovasc. Disord.17(1), 1–9 (2017).
   PubMedGoogle Scholar
• Wang Z , ChenZ, ZhangLet al. Status of hypertension in China: results from the China hypertension survey, 2012–2015. Circulation137(22), 2344–2356 (2018).
   PubMed Web of Science ®Google Scholar